Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of N-3C01 as Monotherapy and in Combination With PD-(L)1 Monoclonal Antibody in Patients With Advanced Malignant Solid Tumors

NCT07639450 is registered in ClinicalTrials.gov with Hefei Xinzhu Biological Technology Co., Ltd. as lead sponsor.

NCT NCT07639450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07639450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of N-3C01 as Monotherapy and in Combination With PD-(L)1 Monoclonal Antibody in Patients With Advanced Malignant Solid Tumors
Lead sponsor
Hefei Xinzhu Biological Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 15, 2026
Completion date
September 30, 2028
Enrollment
114 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumors